Related Experiment Videos
[Congenital hypothyroidism: causes for delayed initiation of treatment]
Insights
Congenital hypothyroidism screening aims to prevent brain dysfunction. Delays in diagnosis and treatment, due to follow-up failures, occurred in three infants with congenital hypothyroidism.
Area of Science:
- Pediatrics
- Endocrinology
- Neonatal Care
Context:
- Neonatal screening programs are crucial for early detection of congenital hypothyroidism.
- Timely intervention prevents severe neurodevelopmental deficits.
- Screening errors can lead to missed diagnoses and delayed treatment.
Purpose:
- To highlight failures in the follow-up of infants with abnormal congenital hypothyroidism screening results.
- To analyze reasons for delayed diagnosis and treatment initiation in three specific cases.
- To underscore the importance of robust follow-up procedures in neonatal screening.
Summary:
- Three infants with congenital hypothyroidism experienced delayed treatment due to screening follow-up failures.
- Reasons included errors in confirmatory testing, parental/physician non-compliance, and delayed diagnosis of central hypothyroidism.
- All cases illustrate critical deficiencies in post-screening management.
Impact:
- Emphasizes the need for improved quality control in neonatal screening follow-up protocols.
- Highlights potential long-term consequences of delayed congenital hypothyroidism treatment.
- Suggests a review of current procedures to prevent similar occurrences.
Abstract:
The aim of neonatal screening programs for congenital hypothyroidism is to ensure early treatment in order to prevent brain dysfunction. There are several reasons why infants are missed in the screening program. We report on three patients with congenital hypothyroidism, who had a pathological screening result and initiation of therapy was delayed. The first patient had an increased TSH level, but she was missed because of mistakes in the confirmatory serum test. During the follow-up the patient showed typical symptoms of hypothyroidism and got a thyroxine supplementation not before the age of three years. The second patient did not get a therapy before the age of six months because of the noncompliance of the parents and physicians. The third patient had a central hypothyroidism. The neonatal screening-program revealed no measurable TSH activity. Although the child had clinical signs of a severe hypothyroidism diagnosis was not made before the age of 5.5 months. Although different reasons are known for screening errors, all these 3 patients were missed because of failures in the follow-up of a pathological screening result, indicating a poor quality in the follow-up procedure.